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Identity 
Other names: CD202B, CD202b, EC 2.7.10.1, hTIE2, 
p140 TEK, TIE-2, TIE2, VMCM, VMCM1 
HGNC (Hugo): TEK 
Location: 9p21.2 
Note: Tie1 and Tie2 [where 'Tie' is an acronym from 
tyrosine kinase with Ig and EGF homology domains] 
are the two members of the Tie family of tyrosine 
kinase receptors. Tie2 has highly conserved sequence 
across vertebrate species, with greatest amino acid
homology occurring in the kinase domain, 
predominantly express on the surface of endothelial 
cells. Three secreted natural ligands have been 
characterized, - Ang1, Ang2 and interspecies orthologs 
Ang3 (mouse) and Ang4 (human). 
DNA/RNA 
Description 
Tie2 DNA contains 121025 bp, which has 23 coding 
exons, in plus strand. 
Transcription 
mRNA contains 4817 bp transcribed in centromeric to 
telomeric orientation; 2 other transcripture structures by 
alternative splicing have been predicted. The mRNA 
contains a long (442 bp) 5'-UTR with 5 upstream ORFs 
and 1 IRES that allows the RNA to be translated under 
hypoxic conditions. 
 
Schematic representation of TEK gene, coding region and protein. UTR, untranslated region; Ig, immunoglobulin; EGF, epithelial growth 
factor. 











Tie2 contains 1124 amino acids and belongs to the 
protein kinase superfamily, Tyr protein kinase family, 
Tie subfamily. Tie2 receptor contains three epidermal 
growth factor (EGF)-like domains flanked by three Ig-
like (immunoglobulin-like) domains, followed by three 
fibronectin type-III domains in the extracellular 
domain. Tie2 possesses one intracellular split tyrosine 
kinase domain, which is highly conserved between the 
Tie members sharing a 76% sequence homology. It 
also contains a single transmembrane domain. 
Expression 
TEK/Tie2 is predominantly expressed by vascular 
endothelial cells: It is detectable in the critical process 
of new vessels formation during early development, 
and in the adult in response to cyclic hormonal 
stimulation in the ovary and uterus, as well as in 
healing skin wounds. High levels of expression of TEK 
are found in placenta, lung, spleen, and heart tissues. 
Hematopoietic stem cells, progenitor and mature 
pericytes, neural progenitor cells, and a subpopulation 
of monocytes (Tie2-expressing monocytes) also 
express Tie2/TEK. In addition, its expression might be 





TEK/Tie2 is a tyrosine-kinase transmembrane receptor 
involved in signaling pathways upon stimuli by 
angiopoietins (natural ligands). It guides the proper 
patterning of endothelial cells during blood vessel 
formation and also plays role in vessel remodeling, cell 
survival, cell migration, and cell-to-matrix and cell-to-
cell adhesion. TEK/Tie2 signaling pathway is also 
involved in Toll-like receptor 2 and integrin signali g. 
Homology 
H. sapiens: TEK; 
P. troglodytes: TEK; 
B. Taurus: TEK; 
M. musculus: Tek; 
D. rerio: tie2; 
R. novergicus: Tek; 
G. gallus: TEK. 
Mutations 
Germinal 
Heterozygous TEK substitutions: R849W (10 of 17 
families with hereditary mucocutaneous venous 
malformation, VMCM), Y897S, Y897C, R915H,  
R918C, V1919L, A925C, K1100N. These mutations 
result in in vitro ligand-independent 
hyperphosphorylation. 
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Somatic 
Several somatic mutations have been identified related 
to non-inherited vascular anomalies: 
1) del-Tie2 mutant, consists in an in-frame deletion of 
129bp, corresponding to a loss of exon 3 and part of 
exon 4 (amino acid 122-165 of extracellular Ig-like 
ligand-binding domain, 43 aa deletion in Ig-like 
domain); 
2) Mutations in exon 17 of TEK/Tie2 in 49,1% (28 of 
57 individuals): two somatic TEK mutations (Y897C, 
R915C) in vascular tumors, and seven somatic TEK 
mutations in vascular malformations (Y897H, Y897C, 
L914F, R915C, S917I, R918C, R918H). 
In patients with human intramuscular haemangioma, 





Cancer: acute myeloid leukemia and chronic 
myelogenous leukemia, and solid tumors, such as 
malignant gliomas, breast cancer, thyroid cancer, 
gastric cancer, bladder cancer, endometrial carcinoma. 
Present in both the vasculature and cancer cells of 
several solid tumors. 
Disease 
Overexpressed in the vasculature of several tumors, as 
breast cancer, non-small cell lung cancer, 
hepatocellular carcinoma, prostate cancer, Kaposi's 
sarcoma, and astrocytoma.  
Overexpressed in the cancer cells -outside of the 
vascular compartment- in acute and chronic myeloid 
leukemia, and solid tumors, such as malignant 
astrocytomas, breast cancer, thyroid cancer, gastric 
cancer, endometrial adenocarcinoma.  
Overexpressed in brain tumor stem cells and leukemic 
blasts. 
Prognosis 
Correlation of TEK/Tie2 expression and malignancy in 
gliomas. Tie2 activation results in increased levels of 
expression of ABC transporter, and eventually 
chemoresistance of malignant gliomas.  
Tie2 regulates migration and invasion of these tumors. 
Cellular Tie2 and soluble Tie2 expression might be 
associated to a higher risk of metastasis in patients with 
breast and bladder cancer, respectively. 
Sporadic and inherited forms of 
mucocutaneous venous malformations 
(VMCM) and intramuscular 
haemangioma 
Disease 
Venous malformations are vascular masses composed 
of dilated channels lined by endothelial cells, with a 
reduced coverage by pericytes, leading to functionally 
low resistance vessels. 
See Mutation section for description of TEK/Tie2 
mutations related with these diseases. Some of these 




Systemic sclerosis: microangiopathies 
Disease 
Systemic sclerosis (SSc) is an autoimmune disease 
characterized by altered angiogenesis that precede 
fibrosis of skin and internal organs. The abnormal 
angiogenesis is one of the major causes of 
microangiopathies. 
Prognosis 
Report suggesting that soluble Tie2 in serum samples 
from patients with systemic sclerosis is related to the 
development of vascular abnormalities of this disease 




Wide range of diseases with a vascular 
and/or inflammatory component, such 
as psoriasis, pulmonary hypertension, 
rheumatoid arthritis 
Disease 
Psoriatic lesions are characterized by elongation and 
dilatation of papillary dermis. Tie2 transgenic mice 
showed epidermal hyperproliferation, inflammatory 
cell accumulation, and altered dermal angiogenesis, 
mimicking the phenotype present in human psoriasis. 
Pulmonary hypertension is characterized by high 
pulmonary arterial pressure. Increased levels of 
activated TEK/Tie2 and Angiopoietin1 have been 
reported. 
Rheumatoid arthritis is characterized by chronic 
inflammatory changes in synovial tissue and 
pathological angiogenesis. Tie2 has been shown to be 
upregulated in synovial tissue of patients with 
rheumatoid arthritis and to mediate pathological 






Cerebrovascular disease: stroke 
Disease 
In stroke, arterial occlusion of one or more arteries in 
the brain leads to focal or global ischemia and tissue 
damage and eventual death. Expression of activated 
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Tie2 and Ang1 lead to enhanced neovascularization, 
vessel stabilization and improved recovery. 
Prognosis 
Reports suggest that activation of Tie2-mediated 
pathway is essential in initiation of survival responses 





Vikkula M, Boon LM, Carraway KL 3rd, Calvert JT, Diamonti 
AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, 
Cantley LC, Mulliken JB, Olsen BR. Vascular 
dysmorphogenesis caused by an activating mutation in the 
receptor tyrosine kinase TIE2. Cell. 1996 Dec 27;87(7):1181-
90 
Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos 
CD, Rao P, Sankar S, Trogan E. Expression of Tie2/Tek in 
breast tumour vasculature provides a new marker for 
evaluation of tumour angiogenesis. Br J Cancer. 
1998;77(1):51-6 
Shewchuk LM, Hassell AM, Ellis B, Holmes WD, Davis R, 
Horne EL, Kadwell SH, McKee DD, Moore JT. Structure of the 
Tie2 RTK domain: self-inhibition by the nucleotide binding loop, 
activation loop, and C-terminal tail. Structure. 2000 Nov 
15;8(11):1105-13 
Jones N, Iljin K, Dumont DJ, Alitalo K. Tie receptors: new 
modulators of angiogenic and lymphangiogenic responses. Nat 
Rev Mol Cell Biol. 2001 Apr;2(4):257-67 
Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. 
Altered expression of angiopoietins and Tie2 endothelium 
receptor in psoriasis. J Invest Dermatol. 2001 May;116(5):713-
20 
Mitsutake N, Namba H, Takahara K, Ishigaki K, Ishigaki J, 
Ayabe H, Yamashita S. Tie-2 and angiopoietin-1 expression in 
human thyroid tumors. Thyroid. 2002 Feb;12(2):95-9 
Müller A, Lange K, Gaiser T, Hofmann M, Bartels H, Feller AC, 
Merz H. Expression of angiopoietin-1 and its receptor TEK in 
hematopoietic cells from patients with myeloid leukemia. Leuk 
Res. 2002 Feb;26(2):163-8 
Shahrara S, Volin MV, Connors MA, Haines GK, Koch AE. 
Differential expression of the angiogenic Tie receptor family in 
arthritic and normal synovial tissue. Arthritis Res. 
2002;4(3):201-8 
Shirakawa K, Shibuya M, Heike Y, Takashima S, Watanabe I, 
Konishi F, Kasumi F, Goldman CK, Thomas KA, Bett A, 
Terada M, Wakasugi H. Tumor-infiltrating endothelial cells and 
endothelial precursor cells in inflammatory breast cancer. Int J 
Cancer. 2002 May 20;99(3):344-51 
DeBusk LM, Chen Y, Nishishita T, Chen J, Thomas JW, Lin 
PC. Tie2 receptor tyrosine kinase, a major mediator of tumor 
necrosis factor alpha-induced angiogenesis in rheumatoid 
arthritis. Arthritis Rheum. 2003 Sep;48(9):2461-71 
Du L, Sullivan CC, Chu D, Cho AJ, Kido M, Wolf PL, Yuan JX, 
Deutsch R, Jamieson SW, Thistlethwaite PA. Signaling 
molecules in nonfamilial pulmonary hypertension. N Engl J 
Med. 2003 Feb 6;348(6):500-9 
Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito 
K, Koh GY, Suda T. Tie2/angiopoietin-1 signaling regulates 
hematopoietic stem cell quiescence in the bone marrow niche. 
Cell. 2004 Jul 23;118(2):149-61 
Takahara K, Iioka T, Furukawa K, Uchida T, Nakashima M, 
Tsukazaki T, Shindo H. Autocrine/paracrine role of the 
angiopoietin-1 and -2/Tie2 system in cell proliferation and 
chemotaxis of cultured fibroblastic synoviocytes in rheumatoid 
arthritis. Hum Pathol. 2004 Feb;35(2):150-8 
Wang H, Zhang Y, Toratani S, Okamoto T. Transformation of 
vascular endothelial cells by a point mutation in the Tie2 gene 
from human intramuscular haemangioma. Oncogene. 2004 
Nov 11;23(53):8700-4 
Zadeh G, Qian B, Okhowat A, Sabha N, Kontos CD, Guha A. 
Targeting the Tie2/Tek receptor in astrocytomas. Am J Pathol. 
2004 Feb;164(2):467-76 
De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, 
Sampaolesi M, Naldini L. Tie2 identifies a hematopoietic 
lineage of proangiogenic monocytes required for tumor vessel 
formation and a mesenchymal population of pericyte 
progenitors. Cancer Cell. 2005 Sep;8(3):211-26 
Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, 
Gehling UM, Schuch G, Hossfeld DK, Fiedler W. Analysis of 
concerted expression of angiogenic growth factors in acute 
myeloid leukemia: expression of angiopoietin-2 represents an 
independent prognostic factor for overall survival. J Clin Oncol. 
2005 Feb 20;23(6):1109-17 
Meunier-Carpentier S, Dales JP, Djemli A, Garcia S, Bonnier 
P, Andrac-Meyer L, Lavaut MN, Allasia C, Charpin C. 
Comparison of the prognosis indication of VEGFR-1 and 
VEGFR-2 and Tie2 receptor expression in breast carcinoma. 
Int J Oncol. 2005 Apr;26(4):977-84 
Wang J, Wu K, Zhang D, Tang H, Xie H, Hong L, Pan Y, Lan 
M, Hu S, Ning X, Fan D. Expressions and clinical significances 
of angiopoietin-1, -2 and Tie2 in human gastric cancer. 
Biochem Biophys Res Commun. 2005 Nov 11;337(1):386-93 
Eklund L, Olsen BR. Tie receptors and their angiopoietin 
ligands are context-dependent regulators of vascular 
remodeling. Exp Cell Res. 2006 Mar 10;312(5):630-41 
Lee OH, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, 
Piao Y, Liu TJ, Lang FF, Bekele BN, Gomez-Manzano C. 
Expression of the receptor tyrosine kinase Tie2 in neoplastic 
glial cells is associated with integrin beta1-dependent adhesion 
to the extracellular matrix. Mol Cancer Res. 2006 
Dec;4(12):915-26 
Macdonald PR, Progias P, Ciani B, Patel S, Mayer U, 
Steinmetz MO, Kammerer RA. Structure of the extracellular 
domain of Tie receptor tyrosine kinases and localization of the 
angiopoietin-binding epitope. J Biol Chem. 2006 Sep 
22;281(38):28408-14 
Park EH, Lee JM, Pelletier J. The Tie2 5' untranslated region is 
inhibitory to 5' end-mediated translation initiation. FEBS Lett. 
2006 Feb 20;580(5):1309-19 
Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, 
Buchner T, Berdel WE, Mesters RM. Expression of 
angiopoietins and their receptor Tie2 in the bone marrow of 
patients with acute myeloid leukemia. Haematologica. 2006 
Sep;91(9):1203-11 
Saito M, Sato Y, Watanabe J, Kuramoto H, Kaba S, Fukuda T. 
Angiogenic factors in normal endometrium and endometrial 
adenocarcinoma. Pathol Int. 2007 Mar;57(3):140-7 
Cui X, Chen J, Zacharek A, Roberts C, Savant-Bhonsale S, 
Chopp M. Treatment of stroke with (Z)-1-[N-(2-aminoethyl)-N-
(2-ammonioethyl) amino] diazen-1-ium-1, 2-diolate and bone 
marrow stromal cells upregulates angiopoietin-1/Tie2 and 
enhances neovascularization. Neuroscience. 2008 Sep 
22;156(1):155-64 






Atlas Genet Cytogenet Oncol Haematol. 2012; 16(9)  673 
Martin V, Liu D, Fueyo J, Gomez-Manzano C. Tie2: a journey 
from normal angiogenesis to cancer and beyond. Histol 
Histopathol. 2008 Jun;23(6):773-80 
Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, 
Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh 
GY, Olsen BR, Alitalo K. Angiopoietins assemble distinct Tie2 
signalling complexes in endothelial cell-cell and cell-matrix 
contacts. Nat Cell Biol. 2008 May;10(5):527-37 
Bai Y, Meng Z, Cui M, Zhang X, Chen F, Xiao J, Shen L, 
Zhang Y. An Ang1-Tie2-PI3K axis in neural progenitor cells 
initiates survival responses against oxygen and glucose 
deprivation. Neuroscience. 2009 May 5;160(2):371-81 
Chen J, Cui X, Zacharek A, Chopp M. Increasing Ang1/Tie2 
expression by simvastatin treatment induces vascular 
stabilization and neuroblast migration after stroke. J Cell Mol 
Med. 2009 Jul;13(7):1348-57 
Cui X, Chen J, Zacharek A, Roberts C, Yang Y, Chopp M. 
Nitric oxide donor up-regulation of SDF1/CXCR4 and 
Ang1/Tie2 promotes neuroblast cell migration after stroke. J 
Neurosci Res. 2009 Jan;87(1):86-95 
Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, 
Mulliken JB, Eklund L, Boon LM, Vikkula M. Somatic mutations 
in angiopoietin receptor gene TEK cause solitary and multiple 
sporadic venous malformations. Nat Genet. 2009 
Jan;41(1):118-24 
Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, 
Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-
Manzano C. Tie2-mediated multidrug resistance in malignant 
gliomas is associated with upregulation of ABC transporters. 
Oncogene. 2009 Jun 18;28(24):2358-63 
Szarvas T, Jäger T, Droste F, Becker M, Kovalszky I, Romics I, 
Ergün S, Rübben H. Serum levels of angiogenic factors and 
their prognostic relevance in bladder cancer. Pathol Oncol 
Res. 2009 Jun;15(2):193-201 
Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes-Santiago N, 
Alonso MM, Aldape K, Colman H, Gomez-Manzano C. 
Tie2/TEK modulates the interaction of glioma and brain tumor 
stem cells with endothelial cells and promotes an invasive 
phenotype. Oncotarget. 2010 Dec;1(8):700-9 
Kamal M, El-Khayat W. Do serum angiopoietin-1, angiopoietin-
2, and their receptor Tie-2 and 4G/5G variant of PAI-1 gene 
have a role in the pathogenesis of preeclampsia? J Investig 
Med. 2011 Oct;59(7):1147-50 
Noda S, Asano Y, Aozasa N, Akamata K, Yamada D, Masui Y, 
Tamaki Z, Kadono T, Sato S. Serum Tie2 levels: clinical 
association with microangiopathies in patients with systemic 
sclerosis. J Eur Acad Dermatol Venereol. 2011 
Dec;25(12):1476-9 
Saber T, Veale DJ, Balogh E, McCormick J, NicAnUltaigh S, 
Connolly M, Fearon U. Toll-like receptor 2 induced 
angiogenesis and invasion is mediated through the Tie2 
signalling pathway in rheumatoid arthritis. PLoS One. 
2011;6(8):e23540 
Ye C, Pan L, Huang Y, Ye R, Han A, Li S, Li X, Wang S. 
Somatic mutations in exon 17 of the TEK gene in vascular 
tumors and vascular malformations. J Vasc Surg. 2011 
Dec;54(6):1760-8 
This article should be referenced as such: 
Hossain MB, Cortes-Santiago N, Liu D, Martin V, Gomez-
Manzano C. TEK (TEK tyrosine kinase, endothelial). Atlas 
Genet Cytogenet Oncol Haematol. 2012; 16(9):669-673. 
